Our RIPTAC therapeutics hold two proteins together: one that is tumor-specific and another that performs an essential function. The novel protein-protein interaction results in selective killing of the cancer cell.
June 2, 2023
U.S. Senator Chris Murphy Highlights New Haven’s Halda Therapeutics as “Innovator of the Month”
February 14, 2023
Halda Therapeutics unveils its first pipeline data for RIPTAC™ therapeutics, a new drug modality, at ASCO GU Symposium
February 14, 2023
The Halda origin story: Taking hold on cancer with a new drug modality